Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Benjamin A Fisher

Showing results (51-60 of 81) with videos related to

Pageof 9
Sort By:
Lancet (London, England)|August 3, 2024
Safety and efficacy of subcutaneous iscalimab (CFZ533) in two distinct populations of patients with Sjögren's disease (TWINSS): week 24 results of a randomised, double-blind, placebo-controlled, phase 2b dose-ranging studyBenjamin A Fisher, Xavier Mariette, Athena Papas, et al.
Annals of the Rheumatic Diseases|December 15, 2016
Standardisation of labial salivary gland histopathology in clinical trials in primary Sjögren's syndromeBenjamin A Fisher, Roland Jonsson, Troy Daniels, et al.
Rheumatology (Oxford, England)|September 19, 2020
A phase 2 randomized, double-blind, placebo-controlled, proof-of-concept study of oral seletalisib in primary Sjögren's syndromeMaria Juarez, Nieves Diaz, Geoffrey I Johnston, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 20, 2019
Immunofibroblasts are pivotal drivers of tertiary lymphoid structure formation and local pathologySaba Nayar, Joana Campos, Charlotte G Smith, et al.
Annals of the Rheumatic Diseases|November 26, 2018
Phosphatidylinositol 3-kinase delta pathway: a novel therapeutic target for Sjögren's syndromeSaba Nayar, Joana Campos, Charlotte G Smith, et al.
Communications Biology|May 4, 2022
Immunofibroblasts regulate LTα3 expression in tertiary lymphoid structures in a pathway dependent on ICOS/ICOSL interactionSaba Nayar, Elena Pontarini, Joana Campos, et al.
Science Immunology|April 17, 2026
The autoantigen TRIM21 assembles proinflammatory immune complexes after lytic cell deathEsther L Jones Evans, Benjamin Demarco, Han Cai, et al.
BMJ Open|March 3, 2026
Pragmatic, open-label, multicentre, randomised controlled trial to guide initial therapy for immune checkpoint inhibitor-induced inflammatory arthritis comparing standard of care (prednisolone) to adalimumab without glucocorticoids: REACT trial protocolBenjamin A Fisher, Anna Rowe, Chris Hodson, et al.
Rheumatology (Oxford, England)|April 15, 2024
British Society for Rheumatology guideline on management of adult and juvenile onset Sjögren diseaseElizabeth J Price, Stuart Benjamin, Michele Bombardieri, et al.
The Lancet. Respiratory Medicine|December 19, 2021
Namilumab or infliximab compared with standard of care in hospitalised patients with COVID-19 (CATALYST): a randomised, multicentre, multi-arm, multistage, open-label, adaptive, phase 2, proof-of-concept trialBenjamin A Fisher, Tonny Veenith, Daniel Slade, et al.
Pageof 9

Showing results (51-60 of 81) with videos related to

Sort By:
Pageof 9
Lancet (London, England)|August 3, 2024
Safety and efficacy of subcutaneous iscalimab (CFZ533) in two distinct populations of patients with Sjögren's disease (TWINSS): week 24 results of a randomised, double-blind, placebo-controlled, phase 2b dose-ranging studyBenjamin A Fisher, Xavier Mariette, Athena Papas, et al.
Annals of the Rheumatic Diseases|December 15, 2016
Standardisation of labial salivary gland histopathology in clinical trials in primary Sjögren's syndromeBenjamin A Fisher, Roland Jonsson, Troy Daniels, et al.
Rheumatology (Oxford, England)|September 19, 2020
A phase 2 randomized, double-blind, placebo-controlled, proof-of-concept study of oral seletalisib in primary Sjögren's syndromeMaria Juarez, Nieves Diaz, Geoffrey I Johnston, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 20, 2019
Immunofibroblasts are pivotal drivers of tertiary lymphoid structure formation and local pathologySaba Nayar, Joana Campos, Charlotte G Smith, et al.
Annals of the Rheumatic Diseases|November 26, 2018
Phosphatidylinositol 3-kinase delta pathway: a novel therapeutic target for Sjögren's syndromeSaba Nayar, Joana Campos, Charlotte G Smith, et al.
Communications Biology|May 4, 2022
Immunofibroblasts regulate LTα3 expression in tertiary lymphoid structures in a pathway dependent on ICOS/ICOSL interactionSaba Nayar, Elena Pontarini, Joana Campos, et al.
Science Immunology|April 17, 2026
The autoantigen TRIM21 assembles proinflammatory immune complexes after lytic cell deathEsther L Jones Evans, Benjamin Demarco, Han Cai, et al.
BMJ Open|March 3, 2026
Pragmatic, open-label, multicentre, randomised controlled trial to guide initial therapy for immune checkpoint inhibitor-induced inflammatory arthritis comparing standard of care (prednisolone) to adalimumab without glucocorticoids: REACT trial protocolBenjamin A Fisher, Anna Rowe, Chris Hodson, et al.
Rheumatology (Oxford, England)|April 15, 2024
British Society for Rheumatology guideline on management of adult and juvenile onset Sjögren diseaseElizabeth J Price, Stuart Benjamin, Michele Bombardieri, et al.
The Lancet. Respiratory Medicine|December 19, 2021
Namilumab or infliximab compared with standard of care in hospitalised patients with COVID-19 (CATALYST): a randomised, multicentre, multi-arm, multistage, open-label, adaptive, phase 2, proof-of-concept trialBenjamin A Fisher, Tonny Veenith, Daniel Slade, et al.
Pageof 9